News | February 09, 2010

U.S. Insurers to Cover Radioembolization for Liver Cancer

February 9, 2010 - About 22,600 cases of primary liver cancer are diagnosed each year in the U.S. and one million annually worldwide, reports the American Cancer Society.

Two of the largest health insurers in the United States have recently approved coverage of radioembolization to treat unresectable liver cancer, marking the largest favorable determinations for reimbursement coverage for this treatment by U.S. insurers.

The most common form of primary liver cancer is hepatocellular carcinoma (HCC), which in the U.S. is commonly caused by alcohol abuse or by the hepatitis B or hepatitis C virus. HCC is the fifth most common form of cancer in the world and is increasing globally due to an increase in the incidence of hepatitis. Treatment options for patients with primary liver cancer are limited as HCC is usually unresectable.

An important technique for treating radioembolization, also called selective internal radiation therapy (SIRT), is a process by which small beads or microspheres, containing the radioactive element yttrium-90, are delivered directly to the tumor using the tumor's own blood supply.

One form of radioembolization, TheraSphere by MDS Nordion, will now be reimbursed. TheraSphere is a low toxicity, liver cancer therapy that consists of millions of micro-glass beads containing radioactive yttrium-90. The product is injected by physicians into the main artery of the patient's liver through a catheter, which allows the treatment to be delivered directly to the tumor via blood vessels. The TheraSphere treatment can generally be administered on an outpatient basis and does not usually require an overnight hospital stay. After treatment, most TheraSphere patients are eligible for further therapeutic options because the procedure preserves liver vascularity.

For more information: www.mdsnordion.com/therasphere

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation